KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...

On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in ...

The Goethe-Institut USA is Germany's offical cultural center with convenient and effective online German courses and internationally recognized language certificates. As the international market ...

U.S. News Travel ranks the best destinations in the USA. We combine expert opinions and user votes to determine the best travel spots in a variety of categories. If you make a purchase from our ...

This was the stock's second consecutive day of gains.

To decide the best summer vacations in the USA, U.S. News considered several factors, including affordability, weather and variety of things to do, plus traveler and expert sentiment. Like what ...

billboard global excl. us the week's most popular songs based on streaming and sales activity from over 200 territories around the world — excluding the united states — as tracked by luminate ...

After hours: March 7 at 6:58:02 PM EST Loading Chart for VRTX ...

Vertex AI is a fully-managed, unified AI development platform for building and using generative AI. This repository is designed to help you get started with Vertex AI. Whether you're new to Vertex AI ...